Immunoassay Interference Blocker Market Size may expand substantially from 2022 to 2028. The growing geriatric population and the increasing prevalence of chronic diseases requiring diagnostic procedures will bolster the demand for immunoassay interference blockers in the foreseeable future. An emerging application of immunoassay interference blocker market kits across several laboratory diagnostic assays will support the industry expansion in the years ahead.
Increasing healthcare expenditure and heavy R&D investment and collaborations by key players to offer a precise diagnosis for diseases like cancer and other infectious diseases and improve the patient's survival rate is likely to boost the market share over the analysis timeline.
Escalating efforts to gain clinical accuracy and improve diagnostic requirements of several diseases and disorders while reducing the degree of errors, along with an upsurge in the research and development activities to offer new drug deliveries and efficient treatment, will augment the industry forecast in the coming years. Furthermore, supportive government initiatives to improve healthcare infrastructure and ensure early disease diagnosis will push the market growth during the projection period.
Antibody interference blockers are gaining immense popularity and may experience significant expansion over the forecast timeframe. These are used to reduce non-specific binding and other interferences, specifically from rheumatoid factor, anti-mouse antibodies, and heterophilic antibodies that can lead to false-positive results in both competitive and paired monoclonal sandwich assays and ensure assay's accuracy. This will augment the segment expansion in the forthcoming years.
The competitive ELISA segment may drive lucrative growth opportunities to the immunoassay interference blocker market due to its ability to use impure or crude samples and selectively bind any antigen that may be present. Moreover, these kits offer high specificity, sensibility, and flexibility and are suitable for complex samples as they do not require purification before measurement.
Biotech and pharma companies may become the eminent end-use segment over the projection period due to their emerging consumer base and inoperative product segmentation to offer high-quality immunoassay. In addition, the increasing research and development activities by key manufacturers to offer better and improved diagnostic products with utmost precision will further lead to industry development.
Europe immunoassay interference blocker market will experience considerable growth during the stipulated timeframe. The existence of major manufacturing firms and escalating R&D investment and activities will boost the market share in the region. Expanding product portfolios and supportive government norms will further augment the industry outlook in the European region.
Some of the notable players changing the immunoassay interference blocker market outlook by adopting several growth strategies are AMS Biotechnology, Abcam, Aviva Systems Biology, Bio-Rad Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Scantibodies Laboratory, and Meridian Bioscience.
In November 2021, Aviva Systems Biology announced its collaboration with YCharOS, Inc. Industry Advisory Committee to improve the evaluation of commercially available antibody reagents.
Lockdown restrictions during the pandemic resulted in industry closures across major economies, impacting the supply chain management and leading to economic fallbacks. In addition, the diversion of R&D funds and investments towards the treatment of COVID-19 substantially hampered the industry growth.
However, the increasing demand for rapid diagnostic procedures and kits for COVID-19 augmented the market growth and will support the industry expansion in the years ahead.
Market, By Product Type
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries: